HC Wainwright & Co. Reiterates Buy on GT Biopharma, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on GT Biopharma (NASDAQ:GTBP) and maintained a $5 price target.
June 05, 2023 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on GT Biopharma (NASDAQ:GTBP) and maintained a $5 price target.
The reiteration of the Buy rating and maintenance of the $5 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for GT Biopharma. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100